优特克单抗(IL-12/IL-23拮抗剂)治疗银屑病的临床研究进展

Progress in Clinical Research of Ustekinumab(IL-12/IL-23 Antagonist) in the Treatment of Psoriasis

优特克单抗是2009年美国FDA批准上市的一种全人源化单克隆抗体,用于成人中、重度斑块型银屑病患者的治疗。该药通过与IL-12/IL-23的p40亚基特异性结合,抑制Thl和Th17细胞的激活及其下游TNF-α,IL-6,IL-17等细胞因子的分泌,从而抑制银屑病的炎症过程。该药可用于斑块型银屑病、银屑病性关节炎以及青少年银屑病的治疗,优于TNF-α拮抗剂的疗效,且具有较少的不良反应和良好的耐受性,在中、重度银屑病的治疗中具有良好前景。

Ustekinumab is a fully humanized monoclonal antibody approved by The FDA in 2009 for the treatment of patients with moderate to severe plaque psoriasis. By specifically binding to The p40 subunit of IL-12/IL-23,the drug inhibits the activation of Thl and Th17 cells and the secretion of downstream cytokines such as TNF-α,IL-6 and IL-17. As a result,it helps to inhibit the inflammation process. The drug can be used for the treatment of plaque psoriasis,psoriatic arthritis and juvenile psoriasis. The curative effect is superior than TNF-α antagonist,and has less adverse reactions and goodtolerance. Ustekinumab has good prospects in the treatment of psoriasis.